Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company pioneering oral therapies for hereditary angioedema (HAE) through bradykinin B2 receptor antagonism. This page provides investors and healthcare stakeholders with timely updates on clinical developments, regulatory milestones, and corporate news.
Access consolidated reports on deucrictibant's Phase 3 trials (RAPIDe-3, CHAPTER-3), partnership announcements, and financial disclosures. Our news collection features verified press releases and objective analyses of treatment advancements in rare disease therapeutics.
Key content includes updates on HAE treatment efficacy data, manufacturing partnerships, intellectual property developments, and conference presentations. Bookmark this page for direct access to PHVS's latest progress in transforming patient care through innovative oral medication alternatives.
Pharvaris (Nasdaq: PHVS) reported its financial results for Q4 and full year 2022, revealing a loss of €39.2 million for Q4 and a total loss of €76.3 million for the year. Cash and equivalents stood at €162 million as of December 31, 2022. Upcoming milestones include the release of top-line data from the CHAPTER-1 Phase 2 study of PHVS416 for hereditary angioedema (HAE), expected in 2H2023, and the completion of a non-clinical toxicology study by YE2023. The company has also adopted deucrictibant as the nonproprietary name for PHA121.
Pharvaris (Nasdaq: PHVS) announced positive results from its Phase 2 RAPIDe-1 trial of PHVS416 for treating hereditary angioedema (HAE) at the 2023 HAEi Regional Conference APAC. The trial, which included 74 participants and evaluated 147 HAE attacks, demonstrated significant symptom reduction at four hours post-treatment with PHVS416 compared to placebo, achieving a nominal p-value <0.0001. All primary and key secondary endpoints were met, with participants using less rescue medication. PHVS416 was well tolerated, with minimal treatment-related adverse events. These findings support ongoing development as a potential oral on-demand therapy for HAE attacks.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
